Publicacións en colaboración con investigadores/as de University Hospital of Geneva (19)

2024

  1. Consecutive or selectively included high bleeding risk patients in the MASTER DAPT screening log and trial

    European Journal of Internal Medicine

  2. Impact of the COVID-19 Pandemic on Global TAVR Activity: The COVID-TAVI Study

    JACC: Cardiovascular Interventions, Vol. 17, Núm. 3, pp. 374-387

  3. Tricuspid valve disease and cardiac implantable electronic devices

    European Heart Journal, Vol. 45, Núm. 5, pp. 346-365

2023

  1. Clinical Setting and Decision-Making

    Revista de Osteoporosis y Metabolismo Mineral, Vol. 15, Núm. 2, pp. 88-91

  2. Impact of multisite artery disease on clinical outcomes after percutaneous coronary intervention: an analysis from the e-Ultimaster registry

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, Núm. 4, pp. 417-426

2022

  1. Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk

    Journal of the American College of Cardiology, Vol. 80, Núm. 13, pp. 1220-1237

  2. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up

    European Heart Journal, Vol. 43, Núm. 11, pp. 1059-1103

  3. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    Cardiovascular research, Vol. 118, Núm. 6, pp. 1385-1412

  4. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    European Heart Journal, Vol. 43, Núm. 11, pp. 1033-1058

  5. Outcomes and regional differences in practice in a worldwide coronary stent registry

    Heart (British Cardiac Society), Vol. 108, Núm. 16, pp. 1310-1318

2021

  1. Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial

    Circulation, Vol. 144, Núm. 15, pp. 1196-1211

  2. Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week

    Journal of the American College of Cardiology, Vol. 77, Núm. 7, pp. 922-936

  3. Dual antiplatelet therapy after PCI in patients at high bleeding risk

    New England Journal of Medicine, Vol. 385, Núm. 18, pp. 1643-1655

  4. Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry

    ESC Heart Failure, Vol. 8, Núm. 6, pp. 4955-4967

  5. Impact of coronary lesion complexity in percutaneous coronary intervention: One-year outcomes from the large, multicentre e-Ultimaster registry

    EuroIntervention, Vol. 16, Núm. 7, pp. 603-612

2020

  1. Outcomes of acute coronary syndromes in coronavirus disease 2019

    Clinical Research in Cardiology

2019

  1. Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study

    American Heart Journal, Vol. 209, pp. 97-105

2018

  1. Long-term prognosis of patients with life-threatening ventricular arrhythmias induced by coronary artery spasm

    Europace, Vol. 20, Núm. 5, pp. 851-858

2013

  1. A novel electrocardiographic index for the diagnosis of diastolic dysfunction

    PLoS ONE, Vol. 8, Núm. 11